SG11202105180PA - 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use - Google Patents
9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their useInfo
- Publication number
- SG11202105180PA SG11202105180PA SG11202105180PA SG11202105180PA SG11202105180PA SG 11202105180P A SG11202105180P A SG 11202105180PA SG 11202105180P A SG11202105180P A SG 11202105180PA SG 11202105180P A SG11202105180P A SG 11202105180PA SG 11202105180P A SG11202105180P A SG 11202105180PA
- Authority
- SG
- Singapore
- Prior art keywords
- pharmaceutical compositions
- substituted amino
- receptor antagonists
- adenosine receptor
- quinazoline derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862774077P | 2018-11-30 | 2018-11-30 | |
PCT/US2019/063136 WO2020112700A1 (en) | 2018-11-30 | 2019-11-26 | 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202105180PA true SG11202105180PA (en) | 2021-06-29 |
Family
ID=69005832
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202105180PA SG11202105180PA (en) | 2018-11-30 | 2019-11-26 | 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use |
Country Status (25)
Country | Link |
---|---|
US (2) | US11312719B2 (en) |
EP (1) | EP3886988A1 (en) |
JP (1) | JP7241871B2 (en) |
KR (1) | KR102653800B1 (en) |
CN (1) | CN113329791A (en) |
AR (1) | AR117164A1 (en) |
AU (1) | AU2019385905B2 (en) |
BR (1) | BR112021010427B1 (en) |
CA (1) | CA3120862A1 (en) |
CL (1) | CL2021001406A1 (en) |
CO (1) | CO2021006888A2 (en) |
CR (1) | CR20210271A (en) |
DO (1) | DOP2021000104A (en) |
EA (1) | EA202191498A1 (en) |
EC (1) | ECSP21036982A (en) |
IL (1) | IL283334A (en) |
JO (2) | JOP20210116A1 (en) |
MA (1) | MA54298A (en) |
MX (1) | MX2021006329A (en) |
NI (1) | NI202100043A (en) |
PE (1) | PE20211768A1 (en) |
PH (1) | PH12021551196A1 (en) |
SG (1) | SG11202105180PA (en) |
TW (1) | TW202039496A (en) |
WO (1) | WO2020112700A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2170959T3 (en) | 2007-06-18 | 2014-01-13 | Merck Sharp & Dohme | ANTIBODIES AGAINST HUMAN PROGRAMMED DEATH RECEPTOR PD-1 |
US11466017B2 (en) | 2011-03-10 | 2022-10-11 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
JP7044375B2 (en) | 2016-05-31 | 2022-03-30 | ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム | Heterocyclic inhibitor of PTPN11 |
SG11202010822SA (en) | 2018-05-02 | 2020-11-27 | Navire Pharma Inc | Substituted heterocyclic inhibitors of ptpn11 |
PE20211050A1 (en) | 2018-08-10 | 2021-06-04 | Navire Pharma Inc | PTPN11 INHIBITORS |
WO2023158626A1 (en) * | 2022-02-16 | 2023-08-24 | Merck Sharp & Dohme Llc | Adenosine receptor antagonists, pharmaceutical compositions and their use thereof |
WO2023201267A1 (en) | 2022-04-13 | 2023-10-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2109577A1 (en) | 1971-03-01 | 1972-09-14 | Boehringer Mannheim Gmbh | 5-nitrofuran and 5-nitrothiophen derivs - a5-antimicrobials |
US3957766A (en) | 1970-06-19 | 1976-05-18 | Boehringer Mannheim G.M.B.H. | Novel nitrofuran compounds and pharmaceutical compositions |
US4713383A (en) | 1984-10-01 | 1987-12-15 | Ciba-Geigy Corporation | Triazoloquinazoline compounds, and their methods of preparation, pharmaceutical compositions, and uses |
GB9524395D0 (en) | 1995-11-29 | 1996-01-31 | Nickerson Biocem Ltd | Promoters |
US6759759B2 (en) | 2000-08-29 | 2004-07-06 | Tamagawa Seiki Kabushiki Kaisha | Rotary contactless connector and non-rotary contactless connector |
CA2463598C (en) | 2001-10-15 | 2009-09-08 | Schering Corporation | Imidazo (4,3-e)-1,2,4-triazolo(1,5-c) pyrimidines as adenosine a2a receptor antagonists |
AR038366A1 (en) | 2001-11-30 | 2005-01-12 | Schering Corp | 1,2,4-TRIAZOLO COMPOUNDS [1,5-C] SUBSTITUTED PYRIMIDINS, ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR, PHARMACEUTICAL COMPOSITIONS, THE USE OF SUCH COMPOUNDS FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE PROCESSING OF DISEASE SYSTEMS AND CENTRAL SYSTEMS A KIT THAT INCLUDES COMBINATION |
KR20050044593A (en) | 2001-11-30 | 2005-05-12 | 쉐링 코포레이션 | Adenosine a2a receptor antagonists |
FI2206517T3 (en) | 2002-07-03 | 2023-10-19 | Ono Pharmaceutical Co | Immunopotentiating compositions comprising anti-PD-L1 antibodies |
JPWO2004029056A1 (en) | 2002-09-24 | 2006-01-26 | 協和醗酵工業株式会社 | [1,2,4] Triazolo [1,5-c] pyrimidine derivatives |
JP4511943B2 (en) | 2002-12-23 | 2010-07-28 | ワイス エルエルシー | Antibody against PD-1 and use thereof |
ES2729974T3 (en) | 2003-01-23 | 2019-11-07 | Ono Pharmaceutical Co | Specific antibody of human PD-1 and CD3 |
US7674791B2 (en) | 2003-04-09 | 2010-03-09 | Biogen Idec Ma Inc. | Triazolopyrazines and methods of making and using the same |
ES2278353T3 (en) | 2003-10-28 | 2007-08-01 | Schering Corporation | PROCEDURE TO PREPARE 5-AMINO-PIRAZOLO- (4,3-E) -1,2,4-TRIAZOLO (1,5-C) SUBSTITUTED PYRIMIDINS. |
AU2005236059B2 (en) | 2004-04-21 | 2009-01-15 | Schering Corporation | Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists |
US7472383B2 (en) | 2004-08-13 | 2008-12-30 | Sun Microsystems, Inc. | System and method for providing exceptional flow control in protected code through memory layers |
JP2008524330A (en) | 2004-12-21 | 2008-07-10 | シェーリング コーポレイション | Pyrazolo [1,5-A] pyrimidine adenosine A2a receptor antagonist |
LT2439273T (en) | 2005-05-09 | 2019-05-10 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
CN105330741B (en) | 2005-07-01 | 2023-01-31 | E.R.施贵宝&圣斯有限责任公司 | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) |
AR057817A1 (en) | 2005-09-19 | 2007-12-19 | Schering Corp | ANTAGONISTS OF THE A2A RECEIVER OF 2-HETEROARIL-PIRAZOLO- [4,3-E] -1,2,4-TRIAZOL- [1,5-C] -PIRIMIDIN ADENOSINE. PHARMACEUTICAL COMPOSITIONS |
WO2008002596A2 (en) | 2006-06-26 | 2008-01-03 | Schering Corporation | Adenosine a2a receptor antagonists |
DK2170959T3 (en) | 2007-06-18 | 2014-01-13 | Merck Sharp & Dohme | ANTIBODIES AGAINST HUMAN PROGRAMMED DEATH RECEPTOR PD-1 |
PE20091101A1 (en) | 2007-12-18 | 2009-07-26 | Pharminox Ltd | 3-SUBSTITUTED-4-OXO-3,4-DIHYDRO-IMIDAZO [5,1-d] [1,2,3,5-TETRACINE-8-CARBOXYL ACID AMIDES AND ITS USE |
AU2009222040A1 (en) | 2008-03-04 | 2009-09-11 | Schering Corporation | Amino-quinoxaline and amino-quinoline compounds for use as adenosine A2a receptor antagonists |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | Pd-1 binding proteins |
US20110159023A1 (en) | 2008-08-25 | 2011-06-30 | Solomon Langermann | Pd-1 antagonists and methods for treating infectious disease |
ES2592216T3 (en) | 2008-09-26 | 2016-11-28 | Dana-Farber Cancer Institute, Inc. | Human anti-PD-1, PD-L1 and PD-L2 antibodies and their uses |
SI2376535T1 (en) | 2008-12-09 | 2017-07-31 | F. Hoffmann-La Roche Ag | Anti-pd-l1 antibodies and their use to enhance t-cell function |
EP2509983B1 (en) | 2009-11-16 | 2014-09-17 | Merck Sharp & Dohme Corp. | FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY |
JP2013512251A (en) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Simultaneous inhibition of PD-L1 / PD-L2 |
TW201840336A (en) | 2011-08-01 | 2018-11-16 | 美商建南德克公司 | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
US9495379B2 (en) | 2012-10-08 | 2016-11-15 | Veritas Technologies Llc | Locality aware, two-level fingerprint caching |
WO2014101113A1 (en) | 2012-12-28 | 2014-07-03 | Merck Sharp & Dohme Corp. | Piperazine-substituted 7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties |
WO2014101120A1 (en) | 2012-12-28 | 2014-07-03 | Merck Sharp & Dohme Corp. | Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties |
WO2015027431A1 (en) | 2013-08-29 | 2015-03-05 | Merck Sharp & Dohme Corp. | 2,2-difluorodioxolo a2a receptor antagonists |
CN107106558A (en) | 2014-11-18 | 2017-08-29 | 默沙东公司 | With A2AThe Aminopyrazine compound of antagonist properties |
US10085991B2 (en) | 2014-12-04 | 2018-10-02 | Merck Sharp & Dohme Corp. | Formulation inhibiting effects of low acid environment |
WO2016126570A1 (en) | 2015-02-06 | 2016-08-11 | Merck Sharp & Dohme Corp. | Aminoquinazoline compounds as a2a antagonist |
WO2016200717A1 (en) | 2015-06-11 | 2016-12-15 | Merck Sharp & Dohme Corp. | Aminopyrazine compounds with a2a antagonist properties |
US10207002B2 (en) | 2015-06-26 | 2019-02-19 | Merck Sharp & Dohme Corp. | Sustained release formulation and tablets prepared therefrom |
WO2017008205A1 (en) | 2015-07-10 | 2017-01-19 | Merck Sharp & Dohme Corp. | Substituted aminoquinazoline compounds as a2a antagonist |
LT3570844T (en) | 2017-01-20 | 2023-11-10 | Arcus Biosciences, Inc. | Azolopyrimidine for the treatment of cancer-related disorders |
US11498923B2 (en) | 2017-12-13 | 2022-11-15 | Merck Sharp & Dohme Llc | Substituted imidazo[1,2-c]quinazolines as A2A antagonists |
JP7391046B2 (en) | 2018-05-18 | 2023-12-04 | インサイト・コーポレイション | Fused pyrimidine derivatives as A2A/A2B inhibitors |
US20220040184A1 (en) | 2018-11-20 | 2022-02-10 | Merck Sharp Dohme Corp. | Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use |
MA55142A (en) | 2018-11-20 | 2022-02-23 | Merck Sharp & Dohme | SUBSTITUTE AMINO-TRIAZOLOPYRIMIDINE AND AMINO-TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITIONS AND THEIR USE |
US20230054411A1 (en) | 2018-11-30 | 2023-02-23 | Merck Sharp & Dohme Corp. | 7-, 8-, and 10-SUBSTITUTED AMINO TRIAZOLO QUINAZOLINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE |
-
2019
- 2019-11-26 MX MX2021006329A patent/MX2021006329A/en unknown
- 2019-11-26 TW TW108142874A patent/TW202039496A/en unknown
- 2019-11-26 CA CA3120862A patent/CA3120862A1/en active Pending
- 2019-11-26 AU AU2019385905A patent/AU2019385905B2/en active Active
- 2019-11-26 JO JOP/2021/0116A patent/JOP20210116A1/en unknown
- 2019-11-26 US US16/695,367 patent/US11312719B2/en active Active
- 2019-11-26 EP EP19827893.9A patent/EP3886988A1/en active Pending
- 2019-11-26 EA EA202191498A patent/EA202191498A1/en unknown
- 2019-11-26 SG SG11202105180PA patent/SG11202105180PA/en unknown
- 2019-11-26 JP JP2021530114A patent/JP7241871B2/en active Active
- 2019-11-26 WO PCT/US2019/063136 patent/WO2020112700A1/en active Application Filing
- 2019-11-26 AR ARP190103450A patent/AR117164A1/en unknown
- 2019-11-26 CN CN201980090487.8A patent/CN113329791A/en active Pending
- 2019-11-26 BR BR112021010427-5A patent/BR112021010427B1/en active IP Right Grant
- 2019-11-26 MA MA054298A patent/MA54298A/en unknown
- 2019-11-26 CR CR20210271A patent/CR20210271A/en unknown
- 2019-11-26 PE PE2021000757A patent/PE20211768A1/en unknown
- 2019-11-26 KR KR1020217019802A patent/KR102653800B1/en active IP Right Grant
- 2019-11-26 JO JOP/2021/0117A patent/JOP20210117A1/en unknown
-
2021
- 2021-05-20 IL IL283334A patent/IL283334A/en unknown
- 2021-05-24 NI NI202100043A patent/NI202100043A/en unknown
- 2021-05-25 EC ECSENADI202136982A patent/ECSP21036982A/en unknown
- 2021-05-25 PH PH12021551196A patent/PH12021551196A1/en unknown
- 2021-05-26 CO CONC2021/0006888A patent/CO2021006888A2/en unknown
- 2021-05-27 DO DO2021000104A patent/DOP2021000104A/en unknown
- 2021-05-27 CL CL2021001406A patent/CL2021001406A1/en unknown
-
2022
- 2022-03-31 US US17/657,515 patent/US20220220117A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
BR112021010427B1 (en) | 2022-09-27 |
JOP20210117A1 (en) | 2023-01-30 |
EA202191498A1 (en) | 2021-08-20 |
CR20210271A (en) | 2021-07-14 |
JOP20210116A1 (en) | 2023-01-30 |
PE20211768A1 (en) | 2021-09-07 |
TW202039496A (en) | 2020-11-01 |
ECSP21036982A (en) | 2021-06-30 |
US20210107904A1 (en) | 2021-04-15 |
AU2019385905B2 (en) | 2023-01-12 |
US11312719B2 (en) | 2022-04-26 |
JP7241871B2 (en) | 2023-03-17 |
MA54298A (en) | 2022-03-09 |
CN113329791A (en) | 2021-08-31 |
WO2020112700A1 (en) | 2020-06-04 |
PH12021551196A1 (en) | 2021-11-29 |
KR102653800B1 (en) | 2024-04-01 |
JP2022511441A (en) | 2022-01-31 |
AR117164A1 (en) | 2021-07-14 |
CL2021001406A1 (en) | 2021-11-12 |
MX2021006329A (en) | 2021-08-11 |
CO2021006888A2 (en) | 2021-06-10 |
KR20210096184A (en) | 2021-08-04 |
BR112021010427A2 (en) | 2021-08-17 |
US20220220117A1 (en) | 2022-07-14 |
EP3886988A1 (en) | 2021-10-06 |
AU2019385905A1 (en) | 2021-06-03 |
NI202100043A (en) | 2021-08-13 |
DOP2021000104A (en) | 2021-07-30 |
IL283334A (en) | 2021-07-29 |
CA3120862A1 (en) | 2020-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL283334A (en) | 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use | |
IL286998A (en) | Pyrimidinone derivatives and their use as shp2 antagonists | |
EP3883576A4 (en) | Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use | |
HK1249502A1 (en) | Pyrido(3,4-d) pyrimidine derivative and pharmaceutically acceptable salt thereof | |
SG11202001340VA (en) | Quinoxaline derivatives as adenosine receptor antagonists | |
ZA202001442B (en) | Macrocycle containing aminopyrazole and pyrimidine and pharmaceutical composition and use thereof | |
IL277144A (en) | Adenosine receptor antagonists and uses thereof | |
EP3999513A4 (en) | Adenosine a2a receptor antagonists and uses thereof | |
IL277744A (en) | Pyrazolotriazolopyrimidine derivatives as a2a receptor antagonist | |
EP3883575A4 (en) | Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use | |
IL268923A (en) | Pharmacologically active alicyclic-substituted pyrazolo[1,5-a]pyrimidine derivatives | |
ZA201902893B (en) | Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof | |
IL285024A (en) | Thiazolopyridine derivatives as adenosine receptor antagonists | |
EP3730492A4 (en) | Substituted pyrazolo[1,5-a]pyrimidine compound and pharmaceutical composition and use thereof | |
SG11202000823WA (en) | Thiazolopyridine derivatives as adenosine receptor antagonists | |
SG11202104081XA (en) | 5-azaindazole derivatives as adenosine receptor antagonists | |
EP3887377A4 (en) | 7-, 8-, and 10-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use | |
SG11202001337XA (en) | Bezimidazole derivatives as adenosine receptor antagonists | |
EP3814356A4 (en) | Triazolotriazine derivatives as a2a receptor antagonists | |
EP3814355A4 (en) | Triazolotriazine derivatives as a2a receptor antagonists | |
IL265560A (en) | Pharmaceutical composition comprising mineralocorticoid receptor antagonist and use thereof |